Empirico Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Jan 2040
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 6, 2026The maintenance fee for Prodrugs of ALOX-15 inhibitors and methods of using the same (US 11,666,588) comes due Dec 6, 2026. Unpaid by Jun 7, 2027, it lapses early.
- 1 fee due Jul 23, 2027The maintenance fee for GalNAc compositions for improving siRNA bioavailability (US 11,879,125) comes due Jul 23, 2027. Unpaid by Jan 24, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,452,738 | Treatment of thymic stromal lymphopoietin (TSLP) related diseases by inhibition of long-form TSLP transcripts In force · From the USPTO record | In force | From the USPTO record | |
| US 11,116,778 | Prodrugs of ALOX-15 inhibitors and methods of using the same In force · From the USPTO record | In force | From the USPTO record | |
| US 11,666,588 | Prodrugs of ALOX-15 inhibitors and methods of using the same In force · From the USPTO record | In force | From the USPTO record | |
| US 10,941,404 | Treatment of angiopoietin like 7 (ANGPTL7) related diseases In force · From the USPTO record | In force | From the USPTO record | |
| US 11,377,658 | Oligonucleotides for Treatment of Angiopoietin Like 4 (ANGPTL4) Related Diseases In force · Medium confidence | In force | Medium confidence | |
| US 12,674,165 | Oligonucleotides for Treatment of Angiopoietin Like 4 (ANGPTL4) Related Diseases In force · Low confidence | In force | Low confidence | |
| US 11,879,125 | GalNAc compositions for improving siRNA bioavailability In force · From the USPTO record | In force | From the USPTO record | |
| US 12,258,564 | GalNAc compositions for improving siRNA bioavailability In force · From the USPTO record | In force | From the USPTO record | |
| US 12,258,563 | Modified Oligonucleotides In force · High confidence | In force | High confidence | |
| US 12,378,556 | Treatment of angiopoietin like 7 (ANGPTL7) related diseases In force · From the USPTO record | In force | From the USPTO record |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
19 pending · 8 no status recorded